CanSense is focused on developing a cost-effective and scalable blood test designed for the early diagnosis of bowel cancer, also known as colorectal cancer. The company aims to create a non-invasive testing solution that can be implemented in primary care settings. This innovative approach seeks to enhance the accuracy of bowel cancer detection while minimizing the need for unnecessary colonoscopies, ultimately helping healthcare professionals reduce the mortality rate associated with colorectal cancers and alleviating the pressure on healthcare systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.